GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmala Biotech Holdings MDMA.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.17

+10.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

C$605,498

FY2021FY2025

Net income

−C$2.2m

FY2021FY2025

Free cash flow

−C$1.1m

FY2021FY2025

Shareholders' equity

C$2.5m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueC$605,498C$1.0mC$532,003C$78,070—
Research and developmentC$243,935C$125,287C$166,522——
Operating income−C$2.1m−C$643,566−C$762,950−C$985,583−C$2.5m
Net income−C$2.2m−C$823,596−C$779,813−C$985,583−C$2.5m
Diluted earnings per share-0.02-0.01-0.01-0.01-0.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsC$3.4mC$2.9mC$2.4mC$2.3mC$2.8m
Total liabilitiesC$961,732C$916,884C$1.0mC$423,783C$138,479
Shareholders' equityC$2.5mC$2.0mC$1.4mC$1.9mC$2.7m
Shares outstanding107m96m86m83m83m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−C$1.0m−C$321,360−C$339,656−C$625,371−C$173,573
Capital spending−C$35,267−C$226,419−C$506,735−C$994,871−C$262,185
Free cash flow−C$1.1m−C$547,779−C$846,391−C$1.6m−C$435,758

Latest quarters

By quarter end

May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
RevenueC$513,232C$280,584C$206,440C$267,376C$135,168C$145,657C$57,297C$82,688
Operating income−C$513,014−C$347,822−C$343,648−C$384,217−C$516,965−C$793,736−C$443,477−C$213,755
Net income−C$499,759−C$337,696−C$409,695−C$361,134−C$524,235−C$810,766−C$479,109−C$224,355
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.01-0.01-0.00
Total assetsC$3.1mC$3.1mC$3.4mC$3.4mC$3.6mC$3.9mC$2.6mC$2.9m
Shareholders' equityC$2.0mC$2.2mC$2.4mC$2.5mC$2.8mC$3.1mC$1.9mC$2.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue97.9%——
Operating income29.5%——
Net income30.2%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-5.4-29.1-15.4-2.1
Price to sales19.423.222.626.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.